您当前的位置:首页科室新闻 >

科室新闻

毛一雷教授关于肝癌标志物GB73的论著发表于Gut杂志
源自:北京协和医院肝脏外科


肝癌仍是目前世界上死亡率第三位的癌症。目前其筛查及术后监测主要指标为甲胎蛋白(AFP),但是其敏感性和特异性较低。GP73是一种新的肝癌检测标志物,近日Gut杂志发表了我科毛一雷教授为第一作者的研究性文章,文章结果显示:GP73在诊断肝癌方面其特异性及敏感性优于AFP。

ABSTRACT

Background and aims:Golgi protein 73 (GP73) as a potential serum marker for hepatocellular carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its significance in the assessment of tumour recurrence after HCC resection remains unknown. The aim of this study was to determine the value of serum GP73 in the diagnosis of HCC.

Methods:Serum GP73 and alpha-fetoprotein (AFP) were compared in a total of 4217 human subjects in this multicentre study, including 1690 healthy adults, 337 hepatitis B virus (HBV) carriers, 512 patients with cirrhosis, 789 patients with HCC, 61 patients with other malignant liver lesions, 206 patients with benign liver lesions and 622 patients with 14 different kinds of non-liver cancers. The main outcome measures were the specificity and sensitivity of GP73 in patients at risk for the development of HCC.

Results:Using 8.5 relative units as a cut-off value, the sensitivity and specificity of serum GP73 for HCC were 74.6%(95%CI71.5%to77.6%)and97.4%(95%CI96.8 to 98.3%), compared with 58.2% (95% CI 55.2% to 62.1%) and 85.3% (95% CI 83.4% to 88.1%) for AFP (p<0.001) using 35ng/ml as a cut-off value. The GP73 level was significantly increased in patients with HCC compared with healthy controls (14.7 vs 1.2, p<0.001). Although GP73 levels in HBV carriers (2.9) and patients with cirrhosis (4.7) were somewhat elevated, they were much lower than that in patients with HCC (p<0.001). GP73 decreased following surgical resection of HCC lesions and increased with tumour recurrence. Fourteen types of non-liver cancers were analysed; all the benign and other malignant liver lesions had moderate elevations of GP73, albeit at a much lower level than in HCC.

Conclusions:GP73 is an accurate serum marker for the detection of HCC and its recurrence after surgery, with higher sensitivity and specificity than AFP. Clinical implementation of serum GP73 measurement as a standard test for HCC is recommended.